中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
6期
851-853
,共3页
雷双根%余小芬%谢春伟%杨世昕%赵瑞君%雷秋模
雷雙根%餘小芬%謝春偉%楊世昕%趙瑞君%雷鞦模
뢰쌍근%여소분%사춘위%양세흔%조서군%뢰추모
乳腺肿瘤%抗肿瘤联合化疗方案%胸腺肽α1%T淋巴细胞亚群
乳腺腫瘤%抗腫瘤聯閤化療方案%胸腺肽α1%T淋巴細胞亞群
유선종류%항종류연합화료방안%흉선태α1%T림파세포아군
Breast neoplasms%Antineoplastic combined chemotherapy protocols%Thymosin alpha 1%T-lymphocyte subsets
目的 探讨胸腺肽α1对乳腺癌新辅助化疗中毒副反应及细胞免疫功能的影响.方法 83例Ⅱb～Ⅲa期乳腺癌患者按入院单双号随机分成治疗组及对照组两组.其中治疗组40例,对照组43例；治疗组采用CEF方案化疗联合胸腺肽α1治疗,对照组单用CEF方案化疗.结果 两组不良反应均为骨髓抑制和胃肠道反应,对照组有≥Ⅱ度胃肠道反应18例(41.9％)、白细胞计数降低24例(55.8％),治疗组分别为9例(22.5％)、13例(32.5％),两组差异均有统计学意义(x2 =6.860、4.559,P=0.009、0.003)；两组均未发生严重血小板下降、严重肝、肾、心功能损害等.化疗前两组CD3、CD4 CD8、CD4/CD8、NK细胞水平差异均无统计学意义(均P＞0.05),化疗后治疗组CD3 CD4 CD8、CD4/CD8、NK细胞水平均较对照组高(t=6.011、8.372、9.023、6.378、5.196,均P＜0.05).结论 胸腺肽α1联合化疗应用于乳腺癌新辅助化疗中,可减轻毒副反应,提高患者的化疗耐受性及免疫功能,改善生活质量.
目的 探討胸腺肽α1對乳腺癌新輔助化療中毒副反應及細胞免疫功能的影響.方法 83例Ⅱb～Ⅲa期乳腺癌患者按入院單雙號隨機分成治療組及對照組兩組.其中治療組40例,對照組43例；治療組採用CEF方案化療聯閤胸腺肽α1治療,對照組單用CEF方案化療.結果 兩組不良反應均為骨髓抑製和胃腸道反應,對照組有≥Ⅱ度胃腸道反應18例(41.9％)、白細胞計數降低24例(55.8％),治療組分彆為9例(22.5％)、13例(32.5％),兩組差異均有統計學意義(x2 =6.860、4.559,P=0.009、0.003)；兩組均未髮生嚴重血小闆下降、嚴重肝、腎、心功能損害等.化療前兩組CD3、CD4 CD8、CD4/CD8、NK細胞水平差異均無統計學意義(均P＞0.05),化療後治療組CD3 CD4 CD8、CD4/CD8、NK細胞水平均較對照組高(t=6.011、8.372、9.023、6.378、5.196,均P＜0.05).結論 胸腺肽α1聯閤化療應用于乳腺癌新輔助化療中,可減輕毒副反應,提高患者的化療耐受性及免疫功能,改善生活質量.
목적 탐토흉선태α1대유선암신보조화료중독부반응급세포면역공능적영향.방법 83례Ⅱb～Ⅲa기유선암환자안입원단쌍호수궤분성치료조급대조조량조.기중치료조40례,대조조43례；치료조채용CEF방안화료연합흉선태α1치료,대조조단용CEF방안화료.결과 량조불량반응균위골수억제화위장도반응,대조조유≥Ⅱ도위장도반응18례(41.9％)、백세포계수강저24례(55.8％),치료조분별위9례(22.5％)、13례(32.5％),량조차이균유통계학의의(x2 =6.860、4.559,P=0.009、0.003)；량조균미발생엄중혈소판하강、엄중간、신、심공능손해등.화료전량조CD3、CD4 CD8、CD4/CD8、NK세포수평차이균무통계학의의(균P＞0.05),화료후치료조CD3 CD4 CD8、CD4/CD8、NK세포수평균교대조조고(t=6.011、8.372、9.023、6.378、5.196,균P＜0.05).결론 흉선태α1연합화료응용우유선암신보조화료중,가감경독부반응,제고환자적화료내수성급면역공능,개선생활질량.
Objective To study the impact of the thymosin alpha 1 on the toxicity and celluar immune function during neoadjuvant chemotherapy of breast cancer.Methods 83 patients of Ⅱ b-Ⅲ a stage breast cancer were randomly divided into two groups:study group(40 patients,neoadjuvant chemotherapy of CEF combined with thymosin α 11.6mg HQD) and control group(43 cases,neoadjuvant chemotherapy of CEF alone).Results Rates of gastrointestinal reaction and bone marrow depression in study group were significantly lower than those in control group.The levels of CD3,CD4,CD4/CD8 and NK in study group were significantly higher than those in control group after chemotherapy.Conclusion The combination of thymosin alpha 1 and neoadjuvant chemotherapy for breast cancer can reduce the toxicity,improve the tolerance,enhance cellular immune function and improve the quality of breast cancer patient's life.
